PeproTech Inc.
Originally published online as doi:10.1189/jlb.0906581 on January 2, 2007

Published online before print January 2, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0906581v1
81/4/907    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmid, M.
Right arrow Articles by Wehkamp, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmid, M.
Right arrow Articles by Wehkamp, J.
(Journal of Leukocyte Biology. 2007;81:907-915.)
© 2007 by Society for Leukocyte Biology

Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn’s disease

Michael Schmid*,{dagger}, Klaus Fellermann*, Peter Fritz{ddagger}, Oliver Wiedow§, Eduard F. Stange* and Jan Wehkamp*,{dagger},1

Departments of
* Internal Medicine I and
{ddagger} Pathology, Robert Bosch Hospital, Stuttgart, Germany;
{dagger} Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; and
§ Department of Dermatology, University of Kiel, Kiel, Germany

1 Correspondence: Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie, Auerbachstr. 112, 70376 Stuttgart, Germany. E-mail: jan.wehkamp{at}ikp-stuttgart.de

ABSTRACT

Elafin (or skin-derived antileukoprotease) and secretory leukocyte protease inhibitor (SLPI) are serine antiproteases antagonizing human neutrophil elastase (HNE), thereby preventing tissue injury from excessive release of proteolytic enzymes by inflammatory cells. Furthermore, elafin and SLPI are "defensin-like" molecules with broad antimicrobial activity. The balance between proteases and antagonists may critically determine inflammatory processes in Crohn’s disease (CD) and ulcerative colitis (UC). Real-time PCR was performed to quantitate colonic, proinflammatory cytokine IL-8, protease (HNE), and antiprotease mRNA (elafin and SLPI) in a total of 340 biopsies from 117 patients (47 CD, 45 UC, 25 controls). Histological inflammation was scored, and HNE, elafin, and SLPI were localized and semiquantified by immunostaining in 51 colonic paraffin sections (23 CD, 11 UC, 17 controls). Proinflammatory IL-8, degree of histological inflammation, and granulocyte content were similar in UC and CD. Elafin stained predominantly in the epithelium and SLPI in mucosal inflammatory cells. HNE mRNA levels and immunostaining were increased equally in both forms of inflammatory bowel disease. Levels of mRNA and immunostaining of the antiproteases elafin and SLPI were enhanced strongly in inflamed versus noninflamed UC. It is surprising that comparing inflamed versus noninflamed CD, this increase was significantly less pronounced for elafin and even lacking for SLPI. Despite comparable degrees of inflammation and protease levels, the induction of both antiproteases was attenuated in CD. This could contribute to the transmural depth of tissue destruction in CD. Elafin and SLPI may be added to the list of defensin-like peptides with diminished induction in CD versus UC.

Key Words: inflammatory bowel disease • antimicrobial peptides




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
E. Kolaczkowska, W. Grzybek, N. van Rooijen, H. Piccard, B. Plytycz, B. Arnold, and G. Opdenakker
Neutrophil elastase activity compensates for a genetic lack of matrix metalloproteinase-9 (MMP-9) in leukocyte infiltration in a model of experimental peritonitis
J. Leukoc. Biol., March 1, 2009; 85(3): 374 - 381.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
J.-F. Colombel, A. J M Watson, and M. F Neurath
The 10 remaining mysteries of inflammatory bowel disease
Gut, April 1, 2008; 57(4): 429 - 433.
[Full Text] [PDF]


Home page
Innate ImmunityHome page
J. Harder, R. Glaser, and J.-M. Schroder
Review: Human antimicrobial proteins effectors of innate immunity
Innate Immunity, December 1, 2007; 13(6): 317 - 338.
[Abstract] [PDF]


Home page
GutHome page
S. Nuding, K. Fellermann, J. Wehkamp, and E. F Stange
Reduced mucosal antimicrobial activity in Crohn's disease of the colon
Gut, September 1, 2007; 56(9): 1240 - 1247.
[Abstract] [Full Text] [PDF]